ChiRhoClin

Executive Summary

ChiRhoClin is a privately held orphan drug pharmaceutical company founded in 1991 and headquartered in Burtonsville, Maryland. The company positions itself as an "Orphan Theranostics" firm, combining diagnostics and therapeutics for rare diseases. It offers contract research organization (CRO) services, leveraging relationships with universities and hospitals, and provides professional services to the pharmaceutical industry. Despite a long operational history, ChiRhoClin maintains a low public profile with limited disclosed financials, pipeline details, or development stage. Its focus on orphan diseases and theranostics suggests potential for niche regulatory advantages, but the lack of clarity on commercial products or clinical-stage assets constrains near-term growth visibility. The company's ability to scale may hinge on securing partnership agreements or advancing proprietary theranostic platforms.

Upcoming Catalysts (preview)

• Q3 2026Announcement of new CRO or partnership agreement35% success
• Q4 2026FDA orphan drug designation for a proprietary theranostic candidate25% success
• Q1 2027Publication of clinical or preclinical data supporting theranostic platform20% success